Bolt Biotherapeutics latina female header iamge

Bolt Biotherapeutics latino male header image

Bolt Biotherapeutics Science Header image

Bolt Biotherapeutics happy couple header image

We leverage the power of the innate and adaptive immune systems with the goal of long-term tumor remissions for patients

Our Approach

Bolt is pioneering a new category of targeted immunotherapies that leverage the precision of antibody targeting with the activation of the innate and adaptive immune systems in the tumor microenvironment.

Understand Our Science

Patients

BDC-1001 is a HER2 Boltbody™ ISAC that is currently in clinical development for the treatment of patients with HER2 positive colorectal, endometrial, gastroesophageal, and metastatic breast cancer.

LEARN ABOUT OUR CLINICAL TRIALS

Scientist working at Bolt Biotherapeutics

Our Team

Bolt is a world-class, inclusive community of fearless innovators committed to delivering transformative treatments to cancer patients with unmet medical needs.

MEET OUR TEAM

Our Approach

Bolt Biotherapeutics is pioneering a new category of targeted immunotherapies that leverage the precision of antibody targeting with the activation of the innate and adaptive immune systems in the tumor microenvironment.

Understand Our Science

Patients

BDC-1001 is a HER2 Boltbody™ ISAC that is currently in clinical development for the treatment of patients with HER2 positive colorectal, endometrial, gastroesophageal, and metastatic breast cancer.

LEARN ABOUT OUR CLINICAL TRIALS

Our Team

Bolt Biotherapeutics is a world-class, inclusive community of fearless innovators committed to delivering transformative treatments to cancer patients with unmet medical needs.

MEET OUR TEAM

Pipeline

Utilizing our Boltbody™ ISAC approach and myeloid biology expertise, we have a built a robust pipeline of immune-stimulating, myeloid-engaging therapeutics.

Proprietary Development Programs

Program
(Target)IndicationDiscoveryPreclinicalPhase 1Phase 2

BDC-1001
HER2

HER2+ Colorectal, Endometrial, Gastroesophageal Cancer

Phase 2

Monotherapy & nivolumab^† combination studyMono and nivolumab combination^†

HER2+ Metastatic Breast Cancer*

Phase 2

Monotherapy & pertuzumab^§ combination studyMono and pertuzumab combination^§

BDC-3042
Dectin-2

Triple-Negative Breast Cancer
Clear Cell Renal Cell Carcinoma
Head & Neck Cancer
Ovarian Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer

Phase 1

Dose-escalation studyDose-escalation study

Next-generation Boltbody™ ISAC Collaborations

Genmab

Funds 3 bispecific Boltbody ISACs through early clinical development

Innovent

Funds 3 Boltbody ISACs through early clinical development

Toray

Funds 1 Boltbody ISAC through early clinical development

^* Previously treated with Enhertu
^† Collaboration using Bristol-Myers Squibb’s PD-1 inhibitor nivolumab
^§ Collaboration using Roche’s HER2 antagonist pertuzumab